Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

Robert J. Motzer,Toni K. Choueiri,Thomas Powles,Mauricio Burotto,María T. Bourlon,James J. Hsieh,Marco Maruzzo,Amishi Yogesh Shah,Cristina Suárez,Carlos H. Barrios,Martin Eduardo Richardet,Camillo Porta,Jeffrey C. Goh,Yoshihiko Tomita,Jens Bedke,Joshua Zhang,Burcin Simsek,Christian Scheffold,Saurabh Gupta,Andrea B. Apolo

Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.

2021

308Background: First-line NIVO+CABO met primary and secondary efficacy endpoints by improving progression-free survival (PFS; HR 0.51, P < 0.0001), overall survival (OS; HR 0.60, P = 0.0010), and o...

Keywords:

overall survival
Oncology
Checkmate
Renal cell carcinoma
Cabozantinib
Nivolumab
Medicine
Internal medicine
Histology
Sunitinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations